In this study, we proposed to utilize E-cad as a biomarker, indicating that the breast tumor would respond well to MEK inhibition, based on our recent study in which E-cad expression resulted in hyper-activation of ERK, downstream of MEK [7]. Here, MAP2K7 is linked to breast neoplasm.